UnitedHealth CEO Faces Key Test Amid Probes, Margin Collapse

Benzinga

UnitedHealth Group CEO Stephen Hemsley faces intense investor scrutiny Tuesday as the company reports second-quarter earnings, according to CNBC. The company is grappling with criminal and civil DOJ probes, collapsing Optum Health margins, and suspended 2025 guidance. UnitedHealth shares have nearly halved since May following sharp profit drops in Medicare Advantage and physician services, prompting the return of Hemsley after CEO Andrew Witty resigned. Analysts are watching for revised full-year EPS guidance, expected at $21.26, and clarity on how Optum Health will recover after billing changes under Medicare’s V28 rules. While some analysts expressed cautious optimism, they expressed concern over misexecution and long-term challenges.

Transcript

00:00It's Benzinga, bringing Wall Street to Main Street.

00:02UnitedHealth Group CEO Stephen Hemsley faces intense investor scrutiny Tuesday as the company

00:06reports second quarter earnings, according to CNBC. The company is grappling with criminal

00:11and civil DOJ probes, collapsing Optum Health margins, and suspended 2025 guidance. UnitedHealth

00:17shares have nearly halved since May, following its sharp profit drops in Medicare Advantage

00:22and Physician Services, prompting the return of Hemsley after CEO Andrew Witte resigned.

00:26Analysts are watching for revised full-year EPS guidance expected at $21.26 and clarity

00:32on how Optum Health will recover after billing changes under Medicare's V28 rules. While

00:38some analysts express cautious optimism, they express concern over missed execution and

00:42long-term challenges. For all things money, visit Benzinga.com.

Category

Transcript

Comments

Recommended